NIAID awards $4.4 million to research potential anthrax attacks

ALBUQUERQUE, N.M. — Lovelace Respiratory Research Institute was recently awarded a $4.4 million contract from the National Institutes of Allergy and Infectious Disease to continue research because of the potential for bioterrorist attacks involving Bacillus anthracis, the causative agent of anthrax.

"Our ability to fast-track any research for many of the most dangerous bioterrorist chemicals used in warfare today is a valuable contribution to the body of research and for the safety of this country," said Robert W. Rubin, CEO and president of LRRI.

The research calls for the development of a large animal model of inhalation anthrax to test medical countermeasures for the treatment of inhalational anthrax. Because animal efficacy information will be central to product licensure for treatment indication, the development of preclinical models of inhalational anthrax disease is essential.